INTRODUCTION: Neurofeedback (NF) or electroencephalogram (EEG)-Biofeedback is a drug-free form of brain training to directly alter the underlying neural mechanisms of cognition and behavior. It is a technique that measures a subject's EEG signal, processes it in real time, with the goal to enable a behavioral modification by modulating brain activity. The most common application of the NF technology is in epilepsies, migraine, attention-deficit/hyperactivity disorder, autism spectrum disorder, affective disorders, and psychotic disorders. Few studies have investigated the use of NF in context of psychosomatic illnesses. Little is known about the use in cancer patients or postcancer survivors despite the high number of this patient group. OBJECTIVES: We here provide a systematic review of the use and effect of NF on symptoms and burden in cancer patients and long-term cancer survivors. METHODS: In conducting this systematic review, we followed the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) Statement. RESULTS: Our search resulted in only 3 experimental studies, 1 observational study, and 2 case reports. Given the heterogeneity of the intervention systems and protocols, no meta-analysis was conducted. CONCLUSION: Altogether, there is initial evidence that NF is a complementary, drug-free, and noninvasive therapy that has the potential to ameliorate symptoms in this patient group, such as pain, fatigue, depression, and sleep. Further studies are highly needed.
INTRODUCTION:Neurofeedback (NF) or electroencephalogram (EEG)-Biofeedback is a drug-free form of brain training to directly alter the underlying neural mechanisms of cognition and behavior. It is a technique that measures a subject's EEG signal, processes it in real time, with the goal to enable a behavioral modification by modulating brain activity. The most common application of the NF technology is in epilepsies, migraine, attention-deficit/hyperactivity disorder, autism spectrum disorder, affective disorders, and psychotic disorders. Few studies have investigated the use of NF in context of psychosomatic illnesses. Little is known about the use in cancerpatients or postcancer survivors despite the high number of this patient group. OBJECTIVES: We here provide a systematic review of the use and effect of NF on symptoms and burden in cancerpatients and long-term cancer survivors. METHODS: In conducting this systematic review, we followed the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) Statement. RESULTS: Our search resulted in only 3 experimental studies, 1 observational study, and 2 case reports. Given the heterogeneity of the intervention systems and protocols, no meta-analysis was conducted. CONCLUSION: Altogether, there is initial evidence that NF is a complementary, drug-free, and noninvasive therapy that has the potential to ameliorate symptoms in this patient group, such as pain, fatigue, depression, and sleep. Further studies are highly needed.
Entities:
Keywords:
EEG biofeedback; cancer patients; neurofeedback; postcancer survivors; psycho-oncology
Authors: Petra Windthorst; Nazar Mazurak; Marvin Kuske; Arno Hipp; Katrin E Giel; Paul Enck; Andreas Nieß; Stephan Zipfel; Martin Teufel Journal: J Psychosom Res Date: 2016-12-05 Impact factor: 3.006
Authors: Sarah Prinsloo; Diane Novy; Larry Driver; Randall Lyle; Lois Ramondetta; Cathy Eng; Jennifer McQuade; Gabriel Lopez; Lorenzo Cohen Journal: Cancer Date: 2017-03-03 Impact factor: 6.860
Authors: Lindsey A Torre; Freddie Bray; Rebecca L Siegel; Jacques Ferlay; Joannie Lortet-Tieulent; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2015-02-04 Impact factor: 508.702
Authors: Janet S de Moor; Angela B Mariotto; Carla Parry; Catherine M Alfano; Lynne Padgett; Erin E Kent; Laura Forsythe; Steve Scoppa; Mark Hachey; Julia H Rowland Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-03-27 Impact factor: 4.254
Authors: J Ferlay; E Steliarova-Foucher; J Lortet-Tieulent; S Rosso; J W W Coebergh; H Comber; D Forman; F Bray Journal: Eur J Cancer Date: 2013-02-26 Impact factor: 9.162
Authors: Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher Journal: PLoS Med Date: 2009-07-21 Impact factor: 11.069
Authors: William E Rosa; Barbara Riegel; Connie M Ulrich; Jesse Chittams; Ryan Quinn; Salimah H Meghani Journal: Oncol Nurs Forum Date: 2021-01-04 Impact factor: 2.172